STXS

Stereotaxis, Inc. (STXS) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Stereotaxis, Inc. designs, manufactures, and markets robotic systems (Robotic Magnetic Navigation) and instruments for interventional laboratories, primarily focusing on cardiac ablation procedures. The company completed the acquisition of Access Point Technologies EP, Inc. (APT) on July 31, 2024, which is now integrated into its operations, providing in-house catheter manufacturing capabilities.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 9% year-over-year. This was driven by a 29% increase in "Disposables, service and accessories" revenue ($5.51M vs $4.27M), partially offset by a 25% decrease in "Systems" revenue ($1.96M vs $2.61M).
• Margin Compression: Gross margin percentage declined from 58% to 54%. Management attributes this to product mix changes and acquisition-related accounting adjustments (fair value write-up of acquired inventory).
• Expense Increases: Operating expenses rose 15% to $9.99 million. General and Administrative (G&A) expenses increased 30% to $4.50 million, primarily due to a $0.50 million loss on the revaluation of contingent consideration from the APT acquisition and amortization of intangible assets.
• Liquidity: Cash used in operating activities was $1.78 million, an improvement from $2.35 million in the prior year, despite a higher net loss, due to favorable changes in working capital (specifically deferred revenue and accounts payable).

Outlook, Risks, and Management Commentary

• Tariff and Trade Risks: The company faces significant uncertainty regarding U.S. tariffs. While a 90-day suspension of reciprocal tariffs with China was announced in May 2025, potential reinstatement of high tariffs (up to 145% previously) could materially impact costs and sales in China. A 10% universal tariff on non-USMCA imports may also increase costs for raw materials sourced from Japan and Europe.
• Regulatory Progress: The company obtained CE marking for the MAGiC catheter in Q1 2025 and is pursuing FDA clearance. The GenesisX RMN System has CE marking and is seeking FDA 510(k) clearance. The Genesis RMN system received approval in China in November 2024.
• Liquidity Position: Management believes existing cash ($10.6 million) is sufficient to fund operations for the next 12 months. However, the company has incurred cumulative net losses of approximately $567.5 million since inception and may need to raise additional capital in the future, which could be dilutive.
• Supply Chain: Ongoing global supply chain disruptions, inflation, and logistics delays remain risks that could affect manufacturing and service capabilities.

Investor Verification Checklist

• Cash Runway: Verify if the $10.6 million cash balance is sufficient given the quarterly burn rate of ~$1.8 million in operating cash flow and the expectation of continued losses in 2025.
• Tariff Impact: Monitor the status of the 90-day tariff suspension with China and the potential impact of the 10% universal tariff on cost of revenue for H2 2025.
• APT Integration: Assess the performance of the acquired APT business (contributed $1.46M revenue in Q1) and the ongoing costs associated with contingent consideration revaluations.
• Regulatory Milestones: Track the timeline for FDA 510(k) clearance for the GenesisX RMN System and the MAGiC catheter, as these are critical for U.S. market expansion.
• Convertible Preferred Stock: Note the existence of Series A Convertible Preferred Stock ($5.3M carrying value) which ranks senior to common stock and accrues cumulative dividends.